| Rituximab vs Dragunov | 28–19 | 59.57% |
| Rituximab vs Reina | 29–17 | 63.04% |
| Rituximab vs Kazuya | 21–19 | 52.50% |
| Rituximab vs Lidia | 14–20 | 41.18% |
| Rituximab vs Heihachi | 18–16 | 52.94% |
| Rituximab vs Bryan | 21–12 | 63.64% |
| Rituximab vs Jin | 16–15 | 51.61% |
| Rituximab vs King | 16–14 | 53.33% |
| Rituximab vs Yoshimitsu | 15–7 | 68.18% |
| Rituximab vs Steve | 10–11 | 47.62% |
| Rituximab vs Azucena | 8–8 | 50.00% |
| Rituximab vs Hwoarang | 7–8 | 46.67% |
| Rituximab vs Asuka | 8–6 | 57.14% |
| Rituximab vs Anna | 7–7 | 50.00% |
| Rituximab vs Xiaoyu | 9–4 | 69.23% |
| Rituximab vs Jack-8 | 3–8 | 27.27% |
| Rituximab vs Leo | 9–2 | 81.82% |
| Rituximab vs Nina | 5–5 | 50.00% |
| Rituximab vs Law | 5–4 | 55.56% |
| Rituximab vs Devil Jin | 5–4 | 55.56% |
| Rituximab vs Claudio | 6–3 | 66.67% |
| Rituximab vs Zafina | 4–3 | 57.14% |
| Rituximab vs Feng | 1–5 | 16.67% |
| Rituximab vs Lili | 0–6 | 0.00% |
| Rituximab vs Shaheen | 4–2 | 66.67% |
| Rituximab vs Paul | 2–3 | 40.00% |
| Rituximab vs Lars | 2–3 | 40.00% |
| Rituximab vs Jun | 4–1 | 80.00% |
| Rituximab vs Alisa | 2–1 | 66.67% |
| Rituximab vs Victor | 2–1 | 66.67% |
| Rituximab vs Eddy | 2–1 | 66.67% |
| Rituximab vs Lee | 2–0 | 100.00% |
| Rituximab vs Panda | 0–2 | 0.00% |
| Rituximab vs Leroy | 2–0 | 100.00% |
| Rituximab vs Clive | 2–0 | 100.00% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.